Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2012

01-02-2012 | Original Article

Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy

Authors: Yoshiro Miyahara, Shinsuke Nishimura, Maho Watanabe, Kenji Ito, Hitoshi Nakashima, Takao Saito

Published in: Clinical and Experimental Nephrology | Issue 1/2012

Login to get access

Abstract

Background

To clarify whether dysfunction of the scavenger receptor (SR) participates in the development of lipoprotein glomerulopathy (LPG) in immunoglobulin Fc receptor γ chain (FcRγ)-deficient mice [FcRγ knock-out (KO) mice] with induced chronic graft-versus-host disease (cGVHD).

Method

In wild-type (WT) and FcRγ KO C57BL/6 mice, cGVHD was induced by injection of lymphoid cells from donor Bm12 mice. At 6 months after injection, the mice were sacrificed and histologically examined. Total RNA was extracted from the kidneys and cytokine, chemokine, and SR transcript expressions were evaluated by reverse transcription-polymerase chain reaction.

Results

Three of 4 female cGVHD(+)/FcRγ KO mice presented LPG in >60% of glomeruli. cGVHD(−) and cGVHD(+)/WT mice did not show LPG. The SRs CD36, CD68, and CXCL16 showed a significant difference in the values of their transcripts between cGVHD(+)/WT and cGVHD(+)/FcRγ KO mice. Among them, only CD36 showed a drastic decline of mRNA expressions in cGVHD(+)/FcRγ KO mice.

Conclusion

CD36 may play a crucial role in the development of LPG in FcRγ KO mice with cGVHD. In addition to the apolipoprotein E mutation, dysfunction of lipid clearance in the kidney might be one of the factors for the development of LPG.
Literature
1.
go back to reference Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13:148–53.PubMed Saito T, Sato H, Kudo K, et al. Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis. 1989;13:148–53.PubMed
2.
go back to reference Saito T, Oikawa S, Sato H, Sasaki J. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron. 1999;83:193–201.PubMedCrossRef Saito T, Oikawa S, Sato H, Sasaki J. Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants. Nephron. 1999;83:193–201.PubMedCrossRef
3.
go back to reference Watanabe Y, Ozaki I, Yoshida F, et al. A case of nephrotic syndrome with glomerular lipoprotein deposition with capillary ballooning and mesangiolysis. Nephron. 1989;51:265–70.PubMedCrossRef Watanabe Y, Ozaki I, Yoshida F, et al. A case of nephrotic syndrome with glomerular lipoprotein deposition with capillary ballooning and mesangiolysis. Nephron. 1989;51:265–70.PubMedCrossRef
4.
go back to reference Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.PubMedCrossRef Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.PubMedCrossRef
5.
go back to reference Karet FE, Lifton RP. Lipoprotein glomerulopathy: a new role for apolipoprotein E? J Am Soc Nephrol. 1997;8:840–2.PubMed Karet FE, Lifton RP. Lipoprotein glomerulopathy: a new role for apolipoprotein E? J Am Soc Nephrol. 1997;8:840–2.PubMed
6.
go back to reference Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (arginine 145 → proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8:820–3.PubMed Oikawa S, Matsunaga A, Saito T, et al. Apolipoprotein E Sendai (arginine 145 → proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 1997;8:820–3.PubMed
7.
go back to reference Konishi K, Saruta T, Kuramochi S, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (apo E Tokyo) with lipoprotein glomerulopathy. Nephron. 1999;83:214–8.PubMedCrossRef Konishi K, Saruta T, Kuramochi S, et al. Association of a novel 3-amino acid deletion mutation of apolipoprotein E (apo E Tokyo) with lipoprotein glomerulopathy. Nephron. 1999;83:214–8.PubMedCrossRef
8.
go back to reference Ando M, Sasaki J, Hua H, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int. 1999;56:1317–23.PubMedCrossRef Ando M, Sasaki J, Hua H, et al. A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int. 1999;56:1317–23.PubMedCrossRef
9.
go back to reference Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56:421–7.PubMedCrossRef Matsunaga A, Sasaki J, Komatsu T, et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int. 1999;56:421–7.PubMedCrossRef
10.
go back to reference Ogawa T, Maruyama K, Hattori H, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol. 2000;14:149–51.PubMedCrossRef Ogawa T, Maruyama K, Hattori H, et al. A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol. 2000;14:149–51.PubMedCrossRef
11.
go back to reference Miyata T, Sugiyama S, Nangaku M, et al. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol. 1999;10:1590–5.PubMed Miyata T, Sugiyama S, Nangaku M, et al. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol. 1999;10:1590–5.PubMed
12.
go back to reference Ishigaki Y, Oikawa S, Suzuki T, et al. Virus-mediated transduction of apolipoprotein E (Apo E)-sendai develops lipoprotein glomerulopathy in apo E-deficient mice. J Biol Chem. 2000;275:31269–73.PubMedCrossRef Ishigaki Y, Oikawa S, Suzuki T, et al. Virus-mediated transduction of apolipoprotein E (Apo E)-sendai develops lipoprotein glomerulopathy in apo E-deficient mice. J Biol Chem. 2000;275:31269–73.PubMedCrossRef
13.
go back to reference Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Role of apolipoprotein E variants in lipoprotein glomerulopathy and other renal lipidoses. Clin Exp Nephrol. 2001;5:201–8.CrossRef Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Role of apolipoprotein E variants in lipoprotein glomerulopathy and other renal lipidoses. Clin Exp Nephrol. 2001;5:201–8.CrossRef
14.
go back to reference Lalazar A, Weisgraber KH, Rall SC Jr, et al. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem. 1988;263:3542–5.PubMed Lalazar A, Weisgraber KH, Rall SC Jr, et al. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem. 1988;263:3542–5.PubMed
15.
go back to reference de Knijff P, van den Maagdenberg A, Frants R, Havekes L. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat. 1994;4:178–94.PubMedCrossRef de Knijff P, van den Maagdenberg A, Frants R, Havekes L. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat. 1994;4:178–94.PubMedCrossRef
16.
go back to reference Oikawa S, Suzuki N, Sakuma E, et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis. 1991;18:553–8.PubMed Oikawa S, Suzuki N, Sakuma E, et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis. 1991;18:553–8.PubMed
17.
go back to reference Chen F, Maldonado MA, Madaio M, Eisenberg RA. The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease. J Immunol. 1998;161:5880–5.PubMed Chen F, Maldonado MA, Madaio M, Eisenberg RA. The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease. J Immunol. 1998;161:5880–5.PubMed
18.
go back to reference Kanamaru Y, Nakao A, Shirato I, et al. Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy. J Am Soc Nephrol. 2002;13:1527–33.PubMedCrossRef Kanamaru Y, Nakao A, Shirato I, et al. Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy. J Am Soc Nephrol. 2002;13:1527–33.PubMedCrossRef
19.
go back to reference Morris SC, Cohen PL, Eisenberg RA. Experimental induction of systemic lupus erythematosus by recognition of foreign Ia. Clin Immunol Immunopathol. 1990;57:263–73.PubMedCrossRef Morris SC, Cohen PL, Eisenberg RA. Experimental induction of systemic lupus erythematosus by recognition of foreign Ia. Clin Immunol Immunopathol. 1990;57:263–73.PubMedCrossRef
20.
go back to reference Slayback DL, Dobkins JA, Harper JM, Allen RD. Genetic factors influencing the development of chronic graft-versus-host disease in a murine model. Bone Marrow Transplant. 2000;26:931–8.PubMedCrossRef Slayback DL, Dobkins JA, Harper JM, Allen RD. Genetic factors influencing the development of chronic graft-versus-host disease in a murine model. Bone Marrow Transplant. 2000;26:931–8.PubMedCrossRef
21.
go back to reference Masutani K, Akahoshi M, Tsuruya K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001;44:2097–106.PubMedCrossRef Masutani K, Akahoshi M, Tsuruya K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001;44:2097–106.PubMedCrossRef
22.
go back to reference Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979;76:333–7.PubMedCrossRef Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979;76:333–7.PubMedCrossRef
23.
go back to reference Bigler RD, Khoo M, Lund-Katz S, Scerbo L, Esfahani M. Identification of low density lipoprotein as a regulator of Fc receptor-mediated phagocytosis. Proc Natl Acad Sci USA. 1990;87:4981–5.PubMedCrossRef Bigler RD, Khoo M, Lund-Katz S, Scerbo L, Esfahani M. Identification of low density lipoprotein as a regulator of Fc receptor-mediated phagocytosis. Proc Natl Acad Sci USA. 1990;87:4981–5.PubMedCrossRef
24.
go back to reference Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988;168:1041–59.PubMedCrossRef Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988;168:1041–59.PubMedCrossRef
25.
go back to reference Stanton LW, White RT, Bryant CM, Protter AA, Endemann G. A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. J Biol Chem. 1992;267:22446–51.PubMed Stanton LW, White RT, Bryant CM, Protter AA, Endemann G. A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. J Biol Chem. 1992;267:22446–51.PubMed
26.
go back to reference Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol. 1998;16:421–32.PubMedCrossRef Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol. 1998;16:421–32.PubMedCrossRef
27.
go back to reference Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76:519–29.PubMedCrossRef Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76:519–29.PubMedCrossRef
28.
go back to reference Morganelli PM, Kennedy SM, Mitchell TI. Differential effects of interferon-gamma on metabolism of lipoprotein immune complexes mediated by specific human macrophage Fc gamma receptors. J Lipid Res. 2000;41:405–15.PubMed Morganelli PM, Kennedy SM, Mitchell TI. Differential effects of interferon-gamma on metabolism of lipoprotein immune complexes mediated by specific human macrophage Fc gamma receptors. J Lipid Res. 2000;41:405–15.PubMed
29.
go back to reference Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: up-regulation by IFN-gamma. J Immunol. 2000;164:4332–9.PubMed Okayama Y, Kirshenbaum AS, Metcalfe DD. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: up-regulation by IFN-gamma. J Immunol. 2000;164:4332–9.PubMed
30.
go back to reference Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049–56.PubMedCrossRef Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049–56.PubMedCrossRef
31.
go back to reference Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res. 1998;39:777–88.PubMed Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res. 1998;39:777–88.PubMed
32.
go back to reference Ikeda H, Mitani T, Ohnuma M, et al. A new platelet-specific antigen, NAKA, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang. 1989;57:213–7.PubMedCrossRef Ikeda H, Mitani T, Ohnuma M, et al. A new platelet-specific antigen, NAKA, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang. 1989;57:213–7.PubMedCrossRef
33.
go back to reference Yamamoto N, Ikeda H, Tandon NN, et al. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36). Blood. 1990;76:1698–703.PubMed Yamamoto N, Ikeda H, Tandon NN, et al. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36). Blood. 1990;76:1698–703.PubMed
Metadata
Title
Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy
Authors
Yoshiro Miyahara
Shinsuke Nishimura
Maho Watanabe
Kenji Ito
Hitoshi Nakashima
Takao Saito
Publication date
01-02-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0554-6

Other articles of this Issue 1/2012

Clinical and Experimental Nephrology 1/2012 Go to the issue

Images in nephrology

“Fatal” gas in the kidney

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine